Last reviewed · How we verify
Zofran inj.+Zofran tab.
Zofran inj.+Zofran tab. is a 5-HT3 receptor antagonist Small molecule drug developed by LG Life Sciences. It is currently FDA-approved for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.
Ondansetron blocks serotonin (5-HT3) receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV), Post-operative nausea and vomiting (PONV), Radiation-induced nausea and vomiting.
At a glance
| Generic name | Zofran inj.+Zofran tab. |
|---|---|
| Sponsor | LG Life Sciences |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology, Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Ondansetron is a selective 5-HT3 receptor antagonist that works centrally and peripherally to inhibit signals that trigger the vomiting reflex. It is particularly effective against chemotherapy-induced nausea and vomiting (CINV) and post-operative nausea and vomiting (PONV) by blocking serotonin signaling in the chemoreceptor trigger zone and on vagal afferent fibers in the gastrointestinal tract.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV)
- Post-operative nausea and vomiting (PONV)
- Radiation-induced nausea and vomiting
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Dizziness
- Fever
Key clinical trials
- Effectiveness of Nalbuphine as an Adjuvant to Subarachnoid Block on Postoperative Analgesia in TURP Surgery (NA)
- Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zofran inj.+Zofran tab. CI brief — competitive landscape report
- Zofran inj.+Zofran tab. updates RSS · CI watch RSS
- LG Life Sciences portfolio CI
Frequently asked questions about Zofran inj.+Zofran tab.
What is Zofran inj.+Zofran tab.?
How does Zofran inj.+Zofran tab. work?
What is Zofran inj.+Zofran tab. used for?
Who makes Zofran inj.+Zofran tab.?
What drug class is Zofran inj.+Zofran tab. in?
What development phase is Zofran inj.+Zofran tab. in?
What are the side effects of Zofran inj.+Zofran tab.?
What does Zofran inj.+Zofran tab. target?
Related
- Drug class: All 5-HT3 receptor antagonist drugs
- Target: All drugs targeting 5-HT3 receptor
- Manufacturer: LG Life Sciences — full pipeline
- Therapeutic area: All drugs in Oncology, Gastroenterology, Anesthesia
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV)
- Indication: Drugs for Post-operative nausea and vomiting (PONV)
- Indication: Drugs for Radiation-induced nausea and vomiting
- Compare: Zofran inj.+Zofran tab. vs similar drugs
- Pricing: Zofran inj.+Zofran tab. cost, discount & access